This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The fact that most insurance contracts explicitly exclude the patient-care costs of clinical trials of investigational agents is an important disincentive for physicians and patients to participate in trials. The extent to which insurance companies enforce the research exclusion is variable, but there are disquieting signs that this tendency is increasing. The National Cancer Institute, together with concerned investigators and members of public interest groups, has begun a dialogue with segments of the insurance industry that will, we hope, lead to a continuation of the productive working relationship that has existed for years and enabled the entry of suitable patients into clinical trials.Despite this obstacle, however, many important trials in oncology are conducted with conventional agents (for example, most breast adjuvant studies). Most clinical investigators have experienced little or no problem with insurance reimbursement to patients in trials where no investigational drug is involved. Currently, the cooperative
Wittes RE. The Cost to Patients of Participating in Clinical Trials-Reply. JAMA. 1989;261(8):1151. doi:10.1001/jama.1989.03420080064025
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: